Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Consensus Target Price from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has received a consensus rating of “Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $17.29.

Several equities analysts recently commented on the company. Roth Mkm started coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd.

Replimune Group Trading Up 2.7 %

Shares of Replimune Group stock opened at $12.55 on Friday. The company’s 50-day moving average price is $12.19 and its 200-day moving average price is $10.45. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a market cap of $858.67 million, a price-to-earnings ratio of -4.11 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, equities analysts expect that Replimune Group will post -2.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after buying an additional 32,555 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Replimune Group by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after purchasing an additional 17,471 shares during the period. Rhumbline Advisers increased its stake in Replimune Group by 7.2% in the 2nd quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after purchasing an additional 5,732 shares during the period. Finally, TD Asset Management Inc lifted its position in Replimune Group by 4.6% in the second quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock valued at $2,249,000 after purchasing an additional 11,094 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.